Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics
Sana signed an agreement with Beam Therapeutics for non-exclusive commercial rights to the Cambridge, Mass.-based biotech’s gene editing system, called CRISPR-Cas12b.
Under the terms of the agreement, Sana will pay Beam an upfront payment of $50 million. Beam may also receive additional payments, for instance upon the achievement of development and sales milestones.
“Gene editing technology is a key component in developing engineered cells as medicines, and we are pleased to have the ability to use the Cas12b system as part of a number of our ex vivo engineered cell programs,” said Steve Harr, Sana’s president and CEO in a statement.
READ MORE